Is There a Mitochondrial Protection via Remote Ischemic Conditioning in Settings of Anticancer Therapy Cardiotoxicity?

被引：3

作者：

Kleinbongard, Petra ^{[1
]}

Andreadou, Ioanna ^{[2
]}

机构：

[1] Univ Essen Gesamthsch, West German Heart & Vasc Ctr, Inst Pathophysiol, Med Sch, Essen, Germany

[2] Natl & Kapodistrian Univ Athens, Fac Pharm, Lab Pharmacol, Athens, Greece

来源：

CURRENT HEART FAILURE REPORTS | 2024年 / 21卷 / 04期

关键词：

Anthracycline; Cancer-treatment; Cardioprotection; Cardiotoxicity; Mitochondria; Remote ischemic conditioning; ELEVATION MYOCARDIAL-INFARCTION; ARTERY-BYPASS SURGERY; PRECONDITIONING PRESERVES; SIGNAL-TRANSDUCTION; CLINICAL-OUTCOMES; CARDIOPROTECTION; DOXORUBICIN; PROTEIN; METABOLISM; INHIBITION;

D O I：

10.1007/s11897-024-00658-w

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of ReviewTo provide an overview of (a) protective effects on mitochondria induced by remote ischemic conditioning (RIC) and (b) mitochondrial damage caused by anticancer therapy. We then discuss the available results of studies on mitochondrial protection via RIC in anticancer therapy-induced cardiotoxicity.Recent FindingsIn three experimental studies in healthy mice and pigs, there was a RIC-mediated protection against anthracycline-induced cardiotoxicity and there was some evidence of improved mitochondrial function with RIC. The RIC-mediated protection was not confirmed in the two available studies in cancer patients. In adult cancer patients, RIC was associated with an adverse outcome. There are no data on mitochondrial function in cancer patients.SummaryStudies in tumor-bearing animals are needed to determine whether RIC does not interfere with the anticancer properties of the drugs and whether RIC actually improves mitochondrial function, ultimately resulting in improved cardiac function.

引用

页码：292 / 304

页数：13

共 122 条

[21] Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost [J].

Efentakis, Panagiotis ;

Andreadou, Ioanna ;

Iliodromitis, Konstantinos E. ;

Triposkiadis, Filippos ;

Ferdinandy, Peter ;

Schulz, Rainer ;

Iliodromitis, Efstathios K. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)

[22] Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib [J].

Efentakis, Panagiotis ;

Doerschmann, Hendrik ;

Witzler, Claudius ;

Siemer, Svenja ;

Nikolaou, Panagiota-Efstathia ;

Kastritis, Efstathios ;

Stauber, Roland ;

Dimopoulos, Meletios Athanasios ;

Wenzel, Philip ;

Andreadou, Ioanna ;

Terpos, Evangelos .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) :1-25

[23] Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin [J].

Efentakis, Panagiotis ;

Kremastiotis, Georgios ;

Varela, Aimilia ;

Nikolaou, Panagiota-Efstathia ;

Papanagnou, Eleni-Dimitra ;

Davos, Constantinos H. ;

Tsoumani, Maria ;

Agrogiannis, Georgios ;

Konstantinidou, Anastasia ;

Kastritis, Efstathios ;

Kanaki, Zoi ;

Iliodromitis, Efstathios K. ;

Klinakis, Apostolos ;

Dimopoulos, Meletios A. ;

Trougakos, Ioannis P. ;

Andreadou, Ioanna ;

Terpos, Evangelos .

BLOOD, 2019, 133 (07) :710-723

[24] Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial [J].

Eitel, Ingo ;

Stiermaier, Thomas ;

Rommel, Karl P. ;

Fuernau, Georg ;

Sandri, Marcus ;

Mangner, Norman ;

Linke, Axel ;

Erbs, Sandra ;

Lurz, Phillip ;

Boudriot, Enno ;

Mende, Meinhard ;

Desch, Steffen ;

Schuler, Gerhard ;

Thiele, Holger .

EUROPEAN HEART JOURNAL, 2015, 36 (44) :3049-+

[25] A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine [J].

Eskandari, Mohammad Reza ;

Moghaddam, Faezeh ;

Shahraki, Jafar ;

Pourahmad, Jalal .

XENOBIOTICA, 2015, 45 (01) :79-87

[26] Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning [J].

Ferdinandy, Peter ;

Andreadou, Ioanna ;

Baxter, Gary F. ;

Botker, Hans Erik ;

Davidson, Sean M. ;

Dobrev, Dobromir ;

Gersh, Bernard J. ;

Heusch, Gerd ;

Lecour, Sandrine ;

Ruiz-Meana, Marisol ;

Zuurbier, Coert J. ;

Hausenloy, Derek J. ;

Schulz, Rainer .

PHARMACOLOGICAL REVIEWS, 2023, 75 (01) :159-216

[27] Remote Ischemic Preconditioning of the Heart: Protective Responses in Functional and Biophysical Properties of Cardiac Mitochondria [J].

Ferko, M. ;

Kancirova, I. ;

Jasova, M. ;

Carnicka, S. ;

Murarikova, M. ;

Waczulikova, I. ;

Sumbalova, Z. ;

Kucharska, J. ;

Ulicna, O. ;

Ravingerova, T. ;

Ziegelhoeffer, A. .

PHYSIOLOGICAL RESEARCH, 2014, 63 :S469-S478

[28] Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [J].

Forghani, Parvin ;

Rashid, Aysha ;

Sun, Fangxu ;

Liu, Rui ;

Li, Dong ;

Lee, Megan R. ;

Hwang, Hyun ;

Maxwell, Joshua T. ;

Mandawat, Anant ;

Wu, Ronghu ;

Salaita, Khalid ;

Xu, Chunhui .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (24)

[29] Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity [J].

Galan-Arriola, Carlos ;

Villena-Gutierrez, Rocio ;

Higuero-Verdejo, Maria, I ;

Diaz-Rengifo, Ivan A. ;

Pizarro, Gonzalo ;

Lopez, Gonzalo J. ;

de Molina-Iracheta, Antonio ;

Perez-Martinez, Claudia ;

Garcia, Rodrigo D. ;

Gonzalez-Calle, David ;

Lobo, Manuel ;

Sanchez, Pedro L. ;

Oliver, Eduardo ;

Cordoba, Raul ;

Fuster, Valentin ;

Sanchez-Gonzalez, Javier ;

Ibanez, Borja .

CARDIOVASCULAR RESEARCH, 2021, 117 (04) :1132-1143

[30] Mitochondrial Quality Control in Cardiac-Conditioning Strategies against Ischemia-Reperfusion Injury [J].

Garcia-Nino, Wylly Ramses ;

Zazueta, Cecilia ;

Buelna-Chontal, Mabel ;

Silva-Palacios, Alejandro .

LIFE-BASEL, 2021, 11 (11)

← 1 2 3 4 5 6 7 8 9 10 →